If a patient does not screen positive for the targeted genetic variant when being screened for a study, is it advisable or is there any obligation for the study team to disclose the results to the patient? The answer isn’t a simple one. For best practices and considerations for including genetic testing in your clinical development strategy, read our article.
Authors:
Aman Khera, MBA, FTOPRA, FRAPS
VP, Regulatory Science, Strategy and Innovation
Derek Ansel, MS, LCGC
Vice President, Therapeutic Strategy Lead, Rare Disease
